17.82
price down icon0.28%   -0.05
after-market Dopo l'orario di chiusura: 18.17 0.35 +1.96%
loading
Precedente Chiudi:
$17.87
Aprire:
$17.96
Volume 24 ore:
1.81M
Relative Volume:
0.71
Capitalizzazione di mercato:
$2.46B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-8.7783
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-3.10%
1M Prestazione:
-6.90%
6M Prestazione:
-46.26%
1 anno Prestazione:
-49.06%
Intervallo 1D:
Value
$17.66
$18.60
Intervallo di 1 settimana:
Value
$17.15
$18.60
Portata 52W:
Value
$16.10
$42.47

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Nome
Apellis Pharmaceuticals Inc
Name
Telefono
617-977-5700
Name
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Name
Dipendente
710
Name
Cinguettio
@ApellisPharma
Name
Prossima data di guadagno
2024-12-05
Name
Ultimi documenti SEC
Name
APLS's Discussions on Twitter

Confronta APLS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
17.82 2.46B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-09 Downgrade BofA Securities Buy → Neutral
2025-05-09 Downgrade Raymond James Strong Buy → Outperform
2025-04-29 Iniziato Cantor Fitzgerald Overweight
2024-12-17 Downgrade Goldman Buy → Neutral
2024-11-21 Iniziato Morgan Stanley Equal-Weight
2024-10-25 Iniziato RBC Capital Mkts Sector Perform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-16 Iniziato William Blair Outperform
2024-05-31 Iniziato Piper Sandler Neutral
2024-02-05 Aggiornamento Jefferies Hold → Buy
2023-12-14 Downgrade Wells Fargo Overweight → Equal Weight
2023-11-09 Iniziato Goldman Buy
2023-11-02 Iniziato Mizuho Neutral
2023-10-06 Aggiornamento JP Morgan Neutral → Overweight
2023-09-15 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-08-29 Reiterato Citigroup Buy
2023-08-03 Downgrade JP Morgan Overweight → Neutral
2023-08-01 Downgrade BofA Securities Buy → Neutral
2023-01-03 Downgrade Wells Fargo Overweight → Equal Weight
2022-11-10 Downgrade Jefferies Buy → Hold
2022-07-19 Iniziato H.C. Wainwright Buy
2022-06-17 Ripresa Stifel Buy
2022-04-14 Downgrade ROTH Capital Neutral → Sell
2021-12-08 Iniziato Wells Fargo Overweight
2021-11-29 Downgrade ROTH Capital Buy → Neutral
2021-09-10 Reiterato BMO Capital Markets Outperform
2021-09-10 Reiterato Credit Suisse Neutral
2021-09-10 Reiterato Needham Buy
2021-09-10 Reiterato Oppenheimer Outperform
2021-09-10 Downgrade Wedbush Outperform → Neutral
2021-08-19 Iniziato Jefferies Buy
2021-08-19 Aggiornamento Wedbush Neutral → Outperform
2021-05-21 Iniziato UBS Buy
2021-04-16 Iniziato Goldman Buy
2020-11-19 Iniziato Needham Buy
2020-09-01 Iniziato Stifel Buy
2020-07-20 Iniziato ROTH Capital Buy
2020-06-17 Iniziato BTIG Research Neutral
2020-04-01 Iniziato Raymond James Strong Buy
2020-03-31 Iniziato BMO Capital Markets Outperform
2020-03-11 Aggiornamento Wedbush Underperform → Neutral
2020-01-07 Iniziato SVB Leerink Mkt Perform
2019-12-19 Iniziato BofA/Merrill Buy
2019-11-22 Iniziato Wedbush Underperform
2019-11-05 Iniziato Credit Suisse Neutral
2019-08-01 Reiterato Cantor Fitzgerald Overweight
2019-07-12 Aggiornamento JP Morgan Neutral → Overweight
2019-03-29 Iniziato Robert W. Baird Outperform
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-07-30 Aggiornamento B. Riley FBR Neutral → Buy
2018-05-24 Iniziato Cantor Fitzgerald Overweight
2018-04-12 Downgrade B. Riley FBR, Inc. Buy → Neutral
2018-02-08 Iniziato B. Riley FBR, Inc. Buy
Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

pulisher
Jun 18, 2025

Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 16, 2025

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 12, 2025

How To Trade (APLS) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 09, 2025

Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo

Jun 09, 2025
pulisher
Jun 09, 2025

Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 07, 2025

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance

Jun 07, 2025
pulisher
Jun 07, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025
pulisher
Jun 06, 2025

Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis Pharmaceuticals and Sobi Present Promising Phase 3 VALIANT Study Results for EMPAVELI in Treating Rare Kidney Diseases at European Renal Association Congress - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Breakthrough: EMPAVELI Achieves 68% Disease Reduction in Rare Kidney Conditions as FDA Decision Approaches - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Ann - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st

May 31, 2025
pulisher
May 31, 2025

(APLS) Long Term Investment Analysis - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World

May 31, 2025
pulisher
May 26, 2025

Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 26, 2025
pulisher
May 24, 2025

Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World

May 24, 2025
pulisher
May 22, 2025

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

May 20, 2025
pulisher
May 20, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

May 20, 2025

Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):